- About us
- About Vaccines
- Media centre
- Become a member
- VE Day 2013
How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access
Vaccines Europe acts as the cohesive voice of the Europe-based vaccine industry sector and is a trusted partner for public authorities. Find out more about our association and contribution to Europe.
With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.
The vaccine industry is actively engaged in research & development of new vaccines that target diseases difficult to treat such as HIV/AIDS, cancer, Alzheimer and malaria among others, in view of improving public health.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.
This year’s European Immunisation Week celebrates 40 years since the introduction of the WHO Expanded Programme on Immunisation (EPI) by the World Health Assembly in 1974. Since its creation, the EPI programme has significantly contributed to guiding the establishment of standardized vaccination schedules for major vaccine-preventable diseases in the Member States, such as TB, tetanus, diphtheria, pertussis, polio, and measles. Read more…
Vaccines Europe was pleased to be invited to attend and play an active role in occasion of the first EU Summit on Chronic Diseases organised and hosted by the European Commission’s Directorate-General for Health & Consumers last 3-4 April 2014.
The Summit brought together a set of high-level stakeholders representatives of governments, public health authorities, research organisations, insurers, industry, patients, and the NGO community to join voices in discussing the increasingly pressing burden posed by chronic diseases in the EU, which is set to rise with the projected demographic change and growing number of elderly. Read more…
Vaccines Europe was pleased to attend the Final Conference of the DG SANCO-funded FLURESP project hosted last 28 March 2014 in Luxembourg, chaired by Dr. Ariel Beresniak from the French University of Paris-Descartes.
Funded under the 2nd EU Health Programme 2008-2013, FLURESP aimed to assess the performance and socio-economic impact of difference response strategies for human influenza pandemics in Europe in order to improve European preparedness planning and support decision-making in the framework of national pandemic preparedness plans. Effective prioritisation requires relevant information to refrain decision makers from premature commitment of resources as well as a willingness to use tools and processes that lead to informed and responsible decisions. Read more…